| Ensuring the integrity of clinical practice guidelines: a tool for protecting patients J Lenzer, JR Hoffman, CD Furberg, JPA Ioannidis Bmj 347, 2013 | 218 | 2013 |
| Why we can’t trust clinical guidelines J Lenzer Bmj 346, 2013 | 215 | 2013 |
| Alteplase for stroke: money and optimistic claims buttress the “brain attack” campaignCommentary: Who pays the guideline writers? Commentary: Thrombolysis in stroke: it works! J Lenzer, C Warlow, JL Saver, CS Kidwell, S Starkman Bmj 324 (7339), 723-729, 2002 | 171 | 2002 |
| Why cancer screening has never been shown to “save lives”—and what we can do about it V Prasad, J Lenzer, DH Newman Bmj 352, 2016 | 170 | 2016 |
| Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence J Lenzer BMJ: British Medical Journal (Online) 369, 2020 | 135 | 2020 |
| FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke J Lenzer Bmj 330 (7489), 440, 2005 | 119 | 2005 |
| FDA is incapable of protecting US “against another Vioxx” J Lenzer BMJ 329 (7477), 1253, 2004 | 100 | 2004 |
| Is widespread screening for hepatitis C justified? RL Koretz, KW Lin, JPA Ioannidis, J Lenzer Bmj 350, 2015 | 66 | 2015 |
| Inhaled insulin is approved in Europe and United States J Lenzer Bmj 332 (7537), 321, 2006 | 61 | 2006 |
| Majority of panelists on controversial new cholesterol guideline have current or recent ties to drug manufacturers J Lenzer BMJ 347, 2013 | 55 | 2013 |
| Bush plans to screen whole US population for mental illness J Lenzer BMJ 328 (7454), 1458, 2004 | 49 | 2004 |
| Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests J Lenzer Bmj 332 (7552), 1233, 2006 | 46 | 2006 |
| FDA warns about using antipsychotic drugs for dementia J Lenzer Bmj 330 (7497), 922, 2005 | 46 | 2005 |
| Pfizer pleads guilty, but drug sales continue to soar J Lenzer BMJ 328 (7450), 1217, 2004 | 44 | 2004 |
| Unnecessary care: are doctors in denial and is profit driven healthcare to blame? J Lenzer Bmj 345, 2012 | 42 | 2012 |
| FDA committee votes to withdraw bevacizumab for breast cancer J Lenzer BMJ 343, 2011 | 36 | 2011 |
| Scandals have eroded US public's confidence in drug industry J Lenzer BMJ 329 (7460), 247, 2004 | 36 | 2004 |
| Truly independent research? J Lenzer BMJ 337, 2008 | 35 | 2008 |
| Why the FDA can’t protect the public J Lenzer, S Brownlee Bmj 341, 2010 | 32 | 2010 |
| Physician health programs under fire J Lenzer BMJ 353, 2016 | 29 | 2016 |
John P.A. IoannidisProfessor of Medicine/Health Research & Policy/Biomedical Data Science/Statistics, Stanford UnivVerified email at stanford.edu
